The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma

Nagler, Rafael M.; Gez, E.; Rubinov, R.; Laufer, Dov; Ben-Aryeh, H.; Gaitini, Diana; Filatov, Margarita; Kuten, Abraham

doi:10.1016/s0003-9969(01)00008-5

Cited by 9 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Salivary gland tissue is thought to be a target organ for IL-2-mediated immunological reactions, inducing lymphocytic infiltration and cytokine production leading to salivary gland hypofunction. Thus, intravenous or subcutaneous administration of IL-2 in patients with metastatic cancer and in patients treated with autologous blood stem cell transplantation for hematological malignancies resulted in xerostomia and salivary gland hypofunction; yet, salivary gland hypofunction returned to baseline within 2 weeks after treatment, e.g., secretion of glandular saliva was decreased by 83-95 and 73-83% for unstimulated parotid and submandibular flow rates, respectively, and decreased by 48-65 and 52-56%, respectively, during stimulated conditions [194][195][196]. IL-2-mediated salivary gland hypofunction may resemble graft versus host disease induced hyposalivation, which may point to similar pathophysiologic mechanisms [195].…”

Section: Immunotherapymentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

383

297

View full text Add to dashboard Cite

Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue. Treatment focus should be on optimized/new approaches to further reduce the dose to the parotids, and particularly submandibular and minor salivary glands, as these glands are major contributors to moistening of oral tissues. Other cancer treatments also induce salivary gland hypofunction, although to a lesser severity, and in the case of chemotherapy and immunotherapy, the adverse effect is temporary. Fields of sparse literature included pediatric cancer populations, cancer chemotherapy, radioactive iodine treatment, total body irradiation/hematopoietic stem cell transplantation, and immunotherapy.

show abstract

Section: Immunotherapymentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

383

297

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that systemic diseases or treatments can affect the function of the salivary gland resulting in changes in the composition of the saliva [22], [23], [24]. Salivary sodium and protein levels were elevated after interleukin-2 (IL-2) treatment in patients.…”

Section: Discussionmentioning

confidence: 99%

Systemic Disease-Induced Salivary Biomarker Profiles in Mouse Models of Melanoma and Non-Small Cell Lung Cancer

et al. 2009

View full text Add to dashboard Cite

BackgroundSaliva (oral fluids) is an emerging biofluid poised for detection of clinical diseases. Although the rationale for oral diseases applications (e.g. oral cancer) is intuitive, the rationale and relationship between systemic diseases and saliva biomarkers are unclear.Methodology/Principal FindingsIn this study, we used mouse models of melanoma and non-small cell lung cancer and compared the transcriptome biomarker profiles of tumor-bearing mice to those of control mice. Microarray analysis showed that salivary transcriptomes were significantly altered in tumor-bearing mice vs. controls. Significant overlapping among transcriptomes of mouse tumors, serum, salivary glands and saliva suggests that salivary biomarkers have multiple origins. Furthermore, we identified that the expression of two groups of significantly altered transcription factors (TFs) Runx1, Mlxipl, Trim30 and Egr1, Tbx1, Nr1d1 in salivary gland tissue of melanoma-bearing mice can potentially be responsible for 82.6% of the up-regulated gene expression and 62.5% of the down-regulated gene expression, respectively, in the saliva of melanoma-bearing mice. We also showed that the ectopic production of nerve growth factor (NGF) in the melanoma tumor tissue as a tumor-released mediator can induce expression of the TF Egr-1 in the salivary gland.ConclusionsTaken together, our data support the conclusion that upon systemic disease development, significant changes can occur in the salivary biomarker profile. Although the origins of the disease-induced salivary biomarkers may be both systemic and local, stimulation of salivary gland by mediators released from remote tumors plays an important role in regulating the salivary surrogate biomarker profiles.

show abstract

“…I 131 therapy) (Solans et al 2001) • Chemotherapy (Jensen et al 2003) • Biological therapy (e.g. interleukin-2) (Nagler et al 2001) • Graft-versus-host disease (Nagler et al 1996) Other causes • Drug treatment † (Davies et al 2001 (Davies 2005b). The initial assessment can be performed by any/all members of the multidisciplinary team (MDT), while the latter assessment should be performed by healthcare professionals with training in oral problems.…”

Section: Patients With Cancer Should Be Regularly Assessed For Salivamentioning

confidence: 99%

“…The aetiology of SGD in oncology patients is very variable (Table 1) (Schubert & Izutsu 1987; Nagler et al. 1996, 2001; Folli et al.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salivary gland dysfunction (‘dry mouth’) in patients with cancer: a consensus statement

Davies

Bagg²,

Laverty

et al. 2010

European Journal of Cancer Care

View full text Add to dashboard Cite

A group of interested professionals was convened to develop some evidence-based recommendations on the management of salivary gland dysfunction (SGD) in oncology patients. A Medline search was performed to identify the literature on SGD. The abstracts of all identified papers were read, and the full texts of all relevant papers were reviewed. The evidence was graded according to the Scottish Intercollegiate Guidelines Network grading system for recommendations in evidence-based guidelines. The summary of the main recommendations are: (1) patients with cancer should be regularly assessed for SGD (grade of recommendation - D); (2) the management of SGD should be individualised (D); (3) consideration should be given to strategies to prevent the development of radiation-induced SGD (C); (4) consideration should be given to treatment of the cause(s) of the SGD (C); (5) the treatment of choice for the symptomatic management of SGD is use of an appropriate saliva stimulant (C); (6) consideration should be given to prevention of the complications of the SGD (D); (7) consideration should be given to treatment of the complications of the SGD (D); and (8) patients with SGD should be regularly reassessed (D).

show abstract

The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma

Cited by 9 publications

References 24 publications

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Systemic Disease-Induced Salivary Biomarker Profiles in Mouse Models of Melanoma and Non-Small Cell Lung Cancer

Salivary gland dysfunction (‘dry mouth’) in patients with cancer: a consensus statement

Contact Info

Product

Resources

About